<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83201</article-id><article-id pub-id-type="doi">10.7554/eLife.83201</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-291611"><name><surname>Schilling</surname><given-names>William HK</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6328-8748</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209668"><name><surname>Jittamala</surname><given-names>Podjanee</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292584"><name><surname>Watson</surname><given-names>James A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5524-0325</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293878"><name><surname>Ekkapongpisit</surname><given-names>Maneerat</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293880"><name><surname>Siripoon</surname><given-names>Tanaya</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293881"><name><surname>Ngamprasertchai</surname><given-names>Thundon</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293882"><name><surname>Luvira</surname><given-names>Viravarn</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9270-3720</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293883"><name><surname>Pongwilai</surname><given-names>Sasithorn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293884"><name><surname>Cruz</surname><given-names>Cintia Valeria</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8393-8536</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209667"><name><surname>Callery</surname><given-names>James J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3218-2166</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293885"><name><surname>Boyd</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293886"><name><surname>Kruabkontho</surname><given-names>Varaporn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293887"><name><surname>Ngernseng</surname><given-names>Thatsanun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293888"><name><surname>Tubprasert</surname><given-names>Jaruwan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293889"><name><surname>Abdad</surname><given-names>Mohammad Yazid</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293890"><name><surname>Piaraksa</surname><given-names>Nattaporn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-206858"><name><surname>Suwannasin</surname><given-names>Kanokon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293891"><name><surname>Hanboonkunupakarn</surname><given-names>Pongtorn</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209669"><name><surname>Hanboonkunupakarn</surname><given-names>Borimas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293892"><name><surname>Sookprome</surname><given-names>Sakol</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293893"><name><surname>Poovorawan</surname><given-names>Kittiyod</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293894"><name><surname>Thaipadungpanit</surname><given-names>Janjira</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6184-3381</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293895"><name><surname>Blacksell</surname><given-names>Stuart</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35017"><name><surname>Imwong</surname><given-names>Mallika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-124380"><name><surname>Tarning</surname><given-names>Joel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4566-4030</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-74086"><name><surname>Taylor</surname><given-names>Walter RJ</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293896"><name><surname>Chotivanich</surname><given-names>Vasin</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293897"><name><surname>Sangketchon</surname><given-names>Chunlanee</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293898"><name><surname>Ruksakul</surname><given-names>Wiroj</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35003"><name><surname>Chotivanich</surname><given-names>Kesinee</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66947"><name><surname>Teixeira</surname><given-names>Mauro Martins</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6944-3008</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-35039"><name><surname>Pukrittayakamee</surname><given-names>Sasithon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35008"><name><surname>Dondorp</surname><given-names>Arjen M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5190-2395</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35005"><name><surname>Day</surname><given-names>Nicholas PJ</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2309-1171</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293899"><name><surname>Piyaphanee</surname><given-names>Watcharapong</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293900"><name><surname>Phumratanaprapin</surname><given-names>Weerapong</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-235652"><name><surname>White</surname><given-names>Nicholas J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1897-1978</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><on-behalf-of>on behalf of the PLATCOV Collaborative Group</on-behalf-of><aff id="aff1"><institution content-type="dept">Mahidol Oxford Tropical Medicine Research Unit</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff2"><institution content-type="dept">Nuffield Department of Medicine</institution>, <institution>Oxford University Clinical Research Unit</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Department of Clinical Tropical Medicine</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff4"><institution content-type="dept">Bangplee Hospital</institution>, <institution>Ministry of Public Health</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff5"><institution content-type="dept">Faculty of Medicine</institution>, <institution>Navamindradhiraj University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff6"><institution content-type="dept">Faculty of Science and Health Technology</institution>, <institution>Navamindradhiraj University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff7"><institution content-type="dept">Department of Biochemistry and Immunology</institution>, <institution>Universidade Federal de Minas Gerais</institution>, <addr-line><named-content content-type="city">Belo Horizonte</named-content></addr-line>, <country>Brazil</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-165403"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><role>Reviewing editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>william@tropmedres.ac</email> (WS);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>nickw@tropmedres.ac</email> (NW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>02</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e83201</elocation-id><history><date date-type="received"><day>02</day><month>09</month><year>2022</year></date><date date-type="accepted"><day>03</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Schilling et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Schilling et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83201-v1.pdf"/><abstract><p><bold>Background:</bold> There is no generally accepted methodology for <italic>in vivo</italic> assessment of antiviral activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has clinically significant antiviral activity <italic>in vivo</italic> is uncertain.</p><p><bold>Methods:</bold> In a multicentre open label, randomized, controlled adaptive platform trial, adult patients with early symptomatic COVID-19 were randomized to one of six treatment arms including high dose oral ivermectin (600µg/kg daily for seven days), the monoclonal antibodies casirivimab and imdevimab (600mg/600mg), and no study drug. The primary outcome was the comparison of viral clearance rates in the modified intention-to-treat population (mITT). This was derived from daily log<sub>10</sub> viral densities in standardized duplicate oropharyngeal swab eluates. This ongoing trial is registered at ClinicalTrials.gov (NCT05041907).</p><p><bold>Results:</bold> Randomization to the ivermectin arm was stopped after enrolling 205 patients into all arms, as the prespecified futility threshold was reached. Following ivermectin the mean estimated rate of SARS-CoV-2 viral clearance was 9.1% slower [95%CI -27.2% to +11.8%; n=45] than in the no drug arm [n=41], whereas in a preliminary analysis of the casirivimab/imdevimab arm it was 52.3% faster [95%CI +7.0% to +115.1%; n=10 (Delta variant) versus n=41].</p><p><bold>Conclusions:</bold> High dose ivermectin did not have measurable antiviral activity in early symptomatic COVID-19. Pharmacometric evaluation of viral clearance rate from frequent serial oropharyngeal qPCR viral density estimates is a highly efficient and well tolerated method of assessing SARS CoV-2 antiviral therapeutics <italic>in vivo</italic>.</p><p><bold>Funding:</bold> 'Finding treatments for COVID-19: A phase 2 multi-centre adaptive platform trial to assess antiviral pharmacodynamics in early symptomatic COVID-19 (PLAT-COV)' is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.</p><p><bold>Clinical trial number:</bold> ClinicalTrials.gov (NCT05041907).</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>223195/Z/21/Z</award-id><principal-award-recipient><name><surname>White</surname><given-names>Nicholas J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>223195/Z/21/Z</award-id><principal-award-recipient><name><surname>Schilling</surname><given-names>William HK</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>223195/Z/21/Z</award-id><principal-award-recipient><name><surname>Schilling</surname><given-names>William HK</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Mauro Martins Teixeira, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The trial was approved by local and national research ethics boards in Thailand (Faculty of Tropical Medicine Ethics Committee, Mahidol University, FTMEC Ref: TMEC 21-058) and the Central Research Ethics Committee (CREC, Bangkok, Thailand, CREC Ref: CREC048/64BP-MED34) and by the Oxford University Tropical Research Ethics Committee (OxTREC, Oxford, UK, OxTREC Ref: 24-21). All patients provided fully informed written consent.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All code and data are openly accessible via GitHub: https://github.com/jwatowatson/PLATCOV-IvermectinSequencing data have been deposited in GISAID.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Watson</collab><collab>J</collab></person-group><year iso-8601-date="2022">2022</year><source>PLATCOV Ivermectin</source><ext-link ext-link-type="uri" xlink:href="https://github.com/jwatowatson/PLATCOV-Ivermectin">https://github.com/jwatowatson/PLATCOV-Ivermectin</ext-link><comment>https://github.com/jwatowatson/PLATCOV-Ivermectin</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-83201-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>